MY148589A - Neurotherapeutic azole compounds - Google Patents
Neurotherapeutic azole compoundsInfo
- Publication number
- MY148589A MY148589A MYPI20061865A MYPI20061865A MY148589A MY 148589 A MY148589 A MY 148589A MY PI20061865 A MYPI20061865 A MY PI20061865A MY PI20061865 A MYPI20061865 A MY PI20061865A MY 148589 A MY148589 A MY 148589A
- Authority
- MY
- Malaysia
- Prior art keywords
- azole compounds
- stroke
- neurotherapeutic
- compounds
- adhd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY148589A true MY148589A (en) | 2013-05-15 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20061865A MY148589A (en) | 2005-04-22 | 2006-04-24 | Neurotherapeutic azole compounds |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (enExample) |
| EP (1) | EP1879873B1 (enExample) |
| JP (1) | JP5035238B2 (enExample) |
| KR (1) | KR101286499B1 (enExample) |
| CN (1) | CN101228138B (enExample) |
| AR (1) | AR053065A1 (enExample) |
| AU (1) | AU2006237798B2 (enExample) |
| BE (1) | BE2021C524I2 (enExample) |
| BR (1) | BRPI0607529B8 (enExample) |
| CA (1) | CA2606258C (enExample) |
| DK (1) | DK1879873T3 (enExample) |
| ES (1) | ES2441765T3 (enExample) |
| FI (1) | FIC20210018I1 (enExample) |
| MX (1) | MX2007013197A (enExample) |
| MY (1) | MY148589A (enExample) |
| NL (1) | NL301106I2 (enExample) |
| PL (1) | PL1879873T3 (enExample) |
| PT (1) | PT1879873E (enExample) |
| RU (1) | RU2418792C2 (enExample) |
| TW (1) | TWI398249B (enExample) |
| WO (1) | WO2006112685A1 (enExample) |
| ZA (1) | ZA200709994B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| WO2008140197A1 (en) * | 2007-05-14 | 2008-11-20 | Sk Holdings Co., Ltd. | Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound |
| US8188301B2 (en) | 2007-06-05 | 2012-05-29 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| CN102026988B (zh) * | 2008-06-05 | 2013-07-03 | 爱思开生物制药株式会社 | 3-取代的丙胺化合物 |
| WO2010150946A1 (en) * | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| KR101783633B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 섬유근육통 증후군의 치료 방법 |
| EP2496228B1 (en) | 2009-11-06 | 2014-01-15 | SK Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| JP6232384B2 (ja) * | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| MY199104A (en) * | 2016-12-14 | 2023-10-13 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
| PL3556349T3 (pl) * | 2016-12-14 | 2022-04-11 | Sk Biopharmaceuticals Co., Ltd. | Preparat ciekły do podawania pozajelitowego zawierający związek karbaminianowy |
| ES2975254T3 (es) * | 2016-12-14 | 2024-07-04 | Sk Biopharmaceuticals Co Ltd | Uso de compuestos de carbamato para la prevención, alivio o tratamiento del prurito |
| JP7090616B2 (ja) * | 2016-12-14 | 2022-06-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物を含む口腔内崩壊錠 |
| WO2018111006A1 (ko) | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| JP7086076B2 (ja) * | 2016-12-14 | 2022-06-17 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用 |
| KR102901908B1 (ko) * | 2016-12-14 | 2025-12-17 | 에스케이바이오팜 주식회사 | 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| KR102900173B1 (ko) * | 2016-12-14 | 2025-12-12 | 에스케이바이오팜 주식회사 | 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도 |
| JP7258901B2 (ja) * | 2017-11-14 | 2023-04-17 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
| WO2019098630A1 (ko) | 2017-11-14 | 2019-05-23 | 에스케이바이오팜 주식회사 | 취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| US11666554B2 (en) * | 2017-11-14 | 2023-06-06 | Sk Biopharmaceuticals Co., Ltd. | Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease |
| US11406620B2 (en) | 2017-11-14 | 2022-08-09 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current |
| EP4545140A3 (en) | 2017-11-14 | 2025-07-09 | SK Biopharmaceuticals Co., Ltd. | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
| KR102900174B1 (ko) * | 2017-11-14 | 2025-12-16 | 에스케이바이오팜 주식회사 | 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| JP7408643B2 (ja) * | 2018-09-21 | 2024-01-05 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用 |
| CA3113052A1 (en) * | 2018-09-21 | 2020-03-26 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus |
| TWI837197B (zh) * | 2018-10-19 | 2024-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基甲酸酯化合物於預防、緩解或治療糖尿病周邊神經病變或化療誘發的周邊神經病變的用途 |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| KR20220104746A (ko) * | 2019-11-22 | 2022-07-26 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법 |
| WO2022031099A1 (ko) * | 2020-08-06 | 2022-02-10 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 경구용 고형 제제 및 이의 제조방법 |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810B (zh) * | 2022-11-15 | 2026-02-13 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| KR100221764B1 (ko) * | 1991-08-22 | 1999-09-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 아미드 테트라졸 acat 억제제 |
| KR100912521B1 (ko) * | 2001-06-25 | 2009-08-18 | 에스케이 주식회사 | 2-헤테로시클릭-1,2-에탄디올의 카바메이트 |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en not_active Ceased
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active Active
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
- 2021-06-28 BE BE2021C524C patent/BE2021C524I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200722085A (en) | Neurotherapeutic azole compounds | |
| EP1778341A4 (en) | DYNAMIC NERVE STIMULATION FOR THE TREATMENT OF DISEASES | |
| MX2011001384A (es) | Composiciones y metodos para tratar trastornos psiquiatricos. | |
| EP1786515A4 (en) | TREATMENT OF THE VEGETABLE NERVOUS SYSTEM | |
| TW200510324A (en) | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist | |
| WO2007025286A3 (en) | Therapy procedure for drug delivery for trigeminal pain | |
| EP2532657A3 (en) | Compounds and methods of use | |
| IL183673A0 (en) | Apparatus and method for the conditioning of muscular fibrils reaction coordination capacity by means of biomechanical stimulation | |
| WO2004041258A8 (fr) | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie | |
| IL190080A0 (en) | Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate trasmembrane drug delivery into the middle ear | |
| EP2086478A4 (en) | DYNAMIC MULDE, ESPECIALLY FOR THE TREATMENT OF HEAD AND NECK PAIN | |
| MA33241B1 (fr) | Composes pour le traitement de troubles metaboliques | |
| EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
| IL184578A0 (en) | Method and composition for treating central nervous system disorders | |
| WO2005099702A3 (en) | R(-)-11-hydroxyaporphine derivatives and uses thereof | |
| WO2007109288A3 (en) | Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use | |
| IL190831A0 (en) | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion | |
| UA97401C2 (ru) | Экструдат с улучшенной маскировкой вкуса | |
| NZ548926A (en) | Inhibitors of TGF-R signaling for treatment of CNS disorders | |
| NZ606276A (en) | Fastening Means | |
| EP1961447A3 (en) | Treating depressive disorders with PKC activators | |
| WO2006023452A3 (en) | Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases | |
| SI1853232T1 (sl) | Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo | |
| IL170710A0 (en) | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | |
| ZA200607641B (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |